

Rational Drug Therapy Program

WVBMS Drug Utilization Board

February 24, 2016



Presented by Stephen A. Small, M.S., R.Ph.

West Virginia University School of Pharmacy





November 2015 Program Summary

EO/PA Status	EO Count	% EO Total	PA Count	% PA Total	Total Count	% of Total
APPROVED	2056	75.48%	2233	57.36%	4289	64.82%
CALLTRACK	0	0.00%	269	6.91%	269	4.07%
CLOSED	62	2.28%	127	3.26%	189	2.86%
DENIED	429	15.75%	932	23.94%	1361	20.57%
INPROCESS	0	3.89%	47	1.21%	47	0.71%
MEDREVIEW	106	2.61%	245	6.29%	351	5.30%
PENDING	71	2.61%	40	1.03%	111	1.68%
Total Program	2724	38.77%	3893	55.41%	6617	94.18%
# Member ID# s	2017	1.35	3201	1.22	6002	1.10



December 2015 Program Summary



EO/PA Status	EO Count	% EO Total	PA Count	% PA Total	Total Count	% of Total
APPROVED	2278	71.14%	2503	57.69%	4781	63.40%
CALLTRACK	0	0.00%	306	7.05%	306	4.06%
CLOSED	53	1.66%	130	3.00%	183	2.43%
DENIED	613	19.14%	1041	23.99%	1654	21.93%
INPROCESS	1	4.56%	55	1.27%	56	0.74%
MEDREVIEW	146	3.47%	256	5.90%	402	5.33%
PENDING	111	3.47%	48	1.11%	159	2.11%
Total Program	3202	40.15%	4339	54.40%	7541	94.55%
# Member ID# s	2381	1.34	3529	1.23	5910	1.28



November 2015 Edit Overrides (EO)



EO Status	7069 Ther.Dup	7073 Early Refill	7026 Disp > Exceeds Max	217 Incarcerated	7230 Claim Amount Threshold	7071 Ingredient Dup
APPROVED	79.14%	81.87%	62.30%	95.41%	93.75%	89.87%
CLOSED	1.96%	2.76%	3.17%	0.92%	3.75%	1.27%
DENIED	13.01%	11.98%	26.59%	2.75%	2.50%	3.80%
INPROCESS	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MEDREVIEW	2.50%	2.00%	4.37%	0.00%	0.00%	3.80%
PENDING	3.39%	1.38%	3.57%	0.92%	0.00%	1.27%
Total EO's	1122	651	252	102	80	79

Edit Override Summary Chart



December 2015 Edit Overrides (EO)


Edit Override Status	7069 Ther.Dup	7073 Early Refill	7026 Disp > Exceeds Max	217 Incarcerated	7071 Ingredient Dup	7155 Max RX Days Supply Limit
APPROVED	74.01%	79.07%	66.01%	89.66%	82.11%	75.00%
CLOSED	1.20%	3.14%	1.31%	4.31%	1.05%	0.00%
DENIED	17.58%	14.50%	25.49%	0.86%	10.53%	10.00%
INPROCESS	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
MEDREVIEW	2.97%	1.64%	4.25%	1.72%	3.16%	5.00%
PENDING	4.24%	1.64%	2.94%	3.45%	3.16%	10.00%
Total EO's	1416	669	306	116	95	80




November 2015 PA Stats

	Atypical Anti- psychotics	Narcotic Withdrawal Agents	Anti- convulsants	Amphet- amines	ADD Agents	Direct Factor XA Inhibitors
APPROVED	70.55%	80.20%	66.18%	70.46%	63.16%	79.12%
CALLTRACK	1.82%	12.29%	2.94%	8.86%	3.95%	4.40%
CLOSED	4.73%	1.71%	2.94%	2.53%	3.29%	5.49%
DENIED	15.45%	4.44%	23.90%	13.08%	17.11%	6.59%
INPROCESS	1.09%	0.34%	0.37%	0.00%	0.00%	1.10%
MEDREVIEW	5.27%	0.68%	2.94%	5.06%	10.53%	2.20%
PENDING	1.09%	0.34%	0.74%	0.00%	1.97%	1.10%
Totals	550	293	272	237	152	91

November 2015 PA Status Graph



November 2015 PA Distribution




December 2015 PA Stats


	Atypical Anti- psychotics	Narcotic Withdrawal Agents	Anti- convulsants	Amphet- amines	Proton Pump Inhibitors
APPROVED	70.32%	80.53%	69.12%	65.49%	56.00%
CALLTRACK	2.32%	10.56%	6.32%	8.63%	4.00%
CLOSED	5.26%	1.98%	3.16%	2.35%	3.43%
DENIED	14.06%	3.96%	15.44%	14.51%	25.14%
INPROCESS	1.39%	0.33%	0.00%	0.00%	0.57%
MEDREVIEW	4.48%	1.65%	4.91%	9.02%	10.86%
PENDING	2.16%	0.99%	1.05%	0.00%	0.00%
Totals	647	303	285	255	175

	ADD Agents	DPP-4 Inhibitors	Alpha-2A Rec. Agonist	Narcotics
APPROVED	63.35%	56.64%	71.70%	50.55%
CALLTRACK	4.35%	5.31%	0.94%	6.59%
CLOSED	1.86%	2.65%	0.94%	3.30%
DENIED	18.63%	31.86%	20.75%	35.16%
INPROCESS	0.62%	0.88%	0.00%	0.00%
MEDREVIEW	10.56%	1.77%	3.77%	3.30%
PENDING	0.62%	0.88%	1.89%	1.10%
Totals	161	113	106	91

December 2015 PA Status Graph



December 2015 PA Distribution



Therapy Duplications by Class

HIC3	Definition	Count
November		
H3A	ANALGESICS, NARCOTICS	273
H2S	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	158
H7C	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	104
A4B	HYPOTENSIVES, SYMPATHOLYTIC	60
H7T	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	59
S2B	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE	46
D4J	PROTON-PUMP INHIBITORS	39
A4D	HYPOTENSIVES, ACE INHIBITORS	36
C4G	INSULINS	31
H4B	ANTICONVULSANTS	29
December		
H3A	ANALGESICS, NARCOTICS	262
H2S	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	149
H2V	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	118
H7C	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	108
J5B	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	97
H4B	ANTICONVULSANTS	74
H7T	ANTIPSYCHOTICS, ATYPICAL, DOPAMINE, & SEROTONIN ANTAG	62
D4J	PROTON-PUMP INHIBITORS	55
H2E	SEDATIVE-HYPNOTICS, NON-BARBITURATE	50
S2B	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE	48

Therapeutic Duplication by Drug

GCN Seqno	Drug Name	Drug Strength	Count
November			
057893	DULOXETINE HCL	60 MG	26
046214	FLUOXETINE HCL	20 MG	26
057892	DULOXETINE HCL	30 MG	24
047430	HYDROCODONE/APAP	5 MG-325MG	23
030623	HYDROCODONE/APAP	10MG-325MG	21
004222	OXYCODONE HCL/APAP	5 MG-325MG	21
000347	CLONIDINE HCL	0.2 MG	20
046405	VENLAFAXINE HCL	150 MG	19
047431	HYDROCODONE/APAP	7.5-325MG	19
048977	OXYCODONE HCL/APAP	10MG-325MG	18
December			
004561	CLONAZEPAM	1 MG	31
047430	HYDROCODONE/APAP	5 MG-325MG	29
046404	VENLAFAXINE HCL	75 MG	26
048977	OXYCODONE HCL/APAP	10MG-325MG	26
046214	FLUOXETINE HCL	20 MG	23
019188	ZOLPIDEM TARTRATE	10 MG	22
004222	OXYCODONE HCL/APAP	5 MG-325MG	21
046229	SERTRALINE HCL	100 MG	20
057893	DULOXETINE HCL	60 MG	20
057892	DULOXETINE HCL	30 MG	19

Other Programs

■ Children Stimulant Program

- Review performed by Child Psychiatrist
- Initial issue turn around response
 - Standardized the initial response
 - Established more definitive Pharmacist review guidelines
 - Standardized an initial approval period to allow time for review
- Documentation from providers was slow at first but as the program has progressed the information is more readily available

■ Diabetes Medication Program

- Program is seeing more readily available and current A1C's
- Therapy is being reviewed and adjusted
- More questions will arise when the 6 month A1C requirement will be implemented
- Questions have arisen during the reviews about increasing A1C's and unresponsive A1C's.

■ Sedative/Hypnotic Program

- Matches other state programs
- Implementation not as noisy as anticipated
- Suspected increase in utilization of trazadone
- WVBMS has added flexibility to the reviews for easier reviews.

CDC BOOST Grant - FYI

- Medication Therapy Management for opioid utilizers (OMTM)
- 3 year interventional grant in conjunction with Injury Prevention Center.
- Program Specifics
 - Data are downloaded to a MTM database
 - Cases are reviewed in order of severity (all disease
 - Pharmacy technician contacts patient and reviews medication history
 - MTM Pain Pharmacist reviews case with patient and sends summation letter to patient and prescriber

Issues

■ Any Questions?